Crossmark

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s40880-017-0241-4

Published Online: 2017-09-11

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Kyung-Hee

Kim, Tae Won http://orcid.org/0000-0001-9522-1997
Kang, Jung-Hun

Kim, Jin-Soo

Ahn, Jin-Seok

Kim, Sun-Young

Yun, Hwan-Jung

Eum, Young-Jun

Koh, Sung Ae

Kim, Min Kyoung

Hong, Yong Sang

Kim, Jeong Eun

Lee, Gyeong-Won
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01313780 at ClinicalTrials.gov

Documents that mention this clinical trial

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
https://doi.org/10.1186/s40880-017-0241-4
Funding

Funding for this research was provided by:

Mundipharma Korea Ltd
License Information

Text and Data Mining valid from 2017-09-11

Version of Record valid from 2017-09-11
More Information

Article History

Received: 30 November 2016

Accepted: 1 September 2017

First Online: 11 September 2017

Document is current

Any future updates will be listed below